Pulmonary Drug Delivery Systems Market Size to Exceed USD 51.47 Bn by 2032

The Pulmonary Drug Delivery Systems Market, estimated at USD 37.57 Bn in 2025, is expected to exhibit a CAGR of 4.6% and reach USD 51.47 Bn by 2032.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

Increasing inorganic growth strategies such as collaboration by key market players to expand its product portfolio is expected to drive market growth over the forecast period. For instance, in September 2025, Bilim Pharmaceuticals, a Turkish company manufacturing and marketing pharmaceutical drugs, H&T Presspart, a global provider of respiratory drug-delivery devices and components to the pharmaceutical sector, and Hovione Technology, a pharmaceutical specialist in the development of innovative pulmonary device technology, announced collaboration to support Bilim Pharmaceutical’s launch in the Turkish market of Ventofor Combi Fix, a formulation of Budesonide Formoterol for Asthma and COPD management, delivered by the PowdAir Plus Dry Powder Inhaler (DPI).

Global Pulmonary Drug Delivery Systems Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.

COVID-19 had a positive impact on the global  pulmonary drug delivery systems market, as pulmonary drug delivery systems were used for the treatment of COVID-19 patients. For instance, according to the data provided by the National Library of Medicine in October 2025, Pulmonary drug delivery was the preferred route of administration for treatment of lung diseases especially in asthma and chronic obstructive pulmonary disease (COPD) and COVID-19 respiratory infection. Pulmonary  drug delivery provide the chance of lowering dose, reducing adverse effects, and increasing the alveolar concentration. The demand for pulmonary drug delivery systems was increased during COVID-19 pandemic thus COVID-19 pandemic has positive impact on global pulmonary drug delivery systems.

Global Pulmonary Drug Delivery Systems Market: Key Developments

In June 2025, United Therapeutics Corporation, a public benefit corporation, announced that the U.S. Food and Drug Administration (FDA) has approved Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability. Tyvaso DPI is one of the easiest ways for patients to administer a prostacyclin, delivering the proven efficacy of treprostinil through a small inhaler that fits in the palm of the patient’s hand

In May 2025, Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries,  announced it will invest in additional inhalation capabilities. The investment will fund the build-out of an additional inhalation testing capacity at the Tampa (US) site specialized in development, clinical, and commercial manufacturing of small molecule-based therapies targeting respiratory diseases and disorders, such as cancer, asthma, and chronic obstructive pulmonary disease (COPD).

Browse 43 Market Data Tables and 39 Figures spread through 233 Pages and in-depth TOC on “Global Pulmonary Drug Delivery Systems Market”, By Product Type (Nebulizers, Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), By Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Allergic Rhinitis, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/pulmonary-drug-delivery-systems-market-3952

Key Takeaways of the Global Pulmonary Drug Delivery Systems Market:

• The global pulmonary drug delivery systems market is expected to exhibit a CAGR of 4.6% during the forecast period due to increasing inorganic growth strategies such as agreement by key market players to expand their product portfolio. For instance, in April 2025, Kindeva Drug Delivery, a global contract development manufacturing organization, has entered into a definitive agreement to acquire iPharma Labs, Inc., a manufacturer of inhaled drugs and formulations. This acquisition combined iPharma’s deep expertise and track record in inhalation formulation and development of liquid, dry powder, and propellant-based therapies with Kindeva’s global expertise in developing, commercializing, and manufacturing inhaled therapies.
• Among product type, Dry Powder Inhalers (DPIs) segment is expected to be the dominant in the global pulmonary drug delivery systems market, owing to increasing inorganic growth strategies such as partnership in order to expand their product portfolio is expected to drive the segment growth over the forecast period. For instance, on May 3, 2025, Hovione, the specialist integrated Contract Development & Manufacturing Organization (CDMO), leader in spray drying and particle engineering, and H&T Presspart, manufacturer of drug delivery devices, has entered in a strategic partnership to advance the development of Presspart's Sunriser Capsule-based Dry Powder Inhaler platform. As part of the joint development partnership, Hovione was exclusively partner with Presspart to exploit the Sunriser device in the field of engineered formulations for dry powder inhalation. Presspart will remain responsible for the manufacturing of the Sunriser device.
• Among Application, Chronic Obstructive Pulmonary Disease (COPD) segment is expected to be the dominant in the global pulmonary drug delivery systems market, owing to increasing organic growth strategies such as product launch by key players in the market to expand its product portfolio. For instance, in May 2025, Alkem Labs, a pharmaceutical company,  has launched Innohaler, a DPI device to make life easier for Asthma and COPD (Chronic Obstructive Pulmonary Disease) patients.
• Among regions, North America is expected to be the dominant region in the global pulmonary drug delivery systems market, owing to the increasing adoption of organic growth straergies such as product launch by the market players to expand their product portfolio. For instance, in September 2025, Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the launch of AirDuo Digihaler (fluticasone propionate and salmeterol) inhalation powder and ArmonAir Digihaler (fluticasone propionate) inhalation powder, two digital maintenance inhalers for patients with asthma in U.S. AirDuo Digihaler is a prescription medicine used to control symptoms of asthma and to prevent symptoms such as wheezing in people 12 years of age and older
• Major players operating in the global pulmonary drug delivery systems market include 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca, Boehringer Ingelheim International GmbH., CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Koninklijke Philips N.V.